Strategic initiative to address Ukraine's urgent need for radiation countermeasures Hemafund's infrastructure ensures secure storage and rapid deployment of emergency treatments Collaboration may potentially generate over $100 million in value for both parties HAIFA, Israel, March 05, 2025 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ:PLUR) (TASE: PLUR) ("Pluri" or the "Company"), a leading biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures, today announced that it has signed an exclusive collaboration agreement with Hemafund Ltd. ("Hemafund"), a Ukrainian umbilical cord blood bank with clinical and research laboratori

KEMPTTHAL, Switzerland and HAIFA, Israel, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Foodtech innovator Ever After Foods (EAF) and global food leader Bühler today announced an expansive cultivated meat collaboration to help food producers around the globe produce cultivated meat efficiently at mass scale. Bühler and Ever After Foods will work together to bring a commercial-scale cultivated meat production system, which allows commercial production at ten-fold lower scale than existing technologies, to market. Bühler aims to foster the development of equipment to enable market-ready, sustainable, healthy, and affordable cellular products that can address increasingly complex food system challen

New investment follows recent private placement of $6.5 million with global investor and entrepreneur, Mr. Alejandro WeinsteinFunds are intended to support Pluri's growth and execution strategy as a global leader in cell-based technology HAIFA, Israel, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ:PLUR) (TASE:PLUR) ("Pluri" or the "Company"), a leading biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures, today announced the pricing of a private placement of $3.5 million by long-term shareholder Merchant Adventure Fund, L.P., a major existing shareholder of Pluri, under the same terms as the previously anno

HAIFA, Israel, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ:PLUR) (TASE: PLUR) ("Pluri" or the "Company"), an innovator in the development of leading cell-based technologies for various indications, congratulates Mesoblast Ltd. ("Mesoblast") and its Chief Executive Officer, Silviu Itescu, on the U.S. Food and Drug Administration (the "FDA") approval of the first MSC-based therapy for steroid-refractory acute graft-versus-host disease ("SR-aGVHD"). This landmark achievement marks a pivotal moment in the advancement of regenerative medicine and highlights the growing clinical and regulatory recognition of MSC therapies' transformative potential. "This milestone is not just a trium

HAIFA, Israel, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ:PLUR) (TASE:PLUR) ("Pluri" or the "Company"), a leading biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures, today announced that its PluriCDMO™ business, launched earlier this year, has been shortlisted for the CDMO of the Year Award by the prestigious Advanced Therapies Awards 2025. "This recognition is particularly meaningful as it comes less than a year after we launched our CDMO division," stated Yaky Yanay, Chief Executive Officer and President of Pluri. "I couldn't be prouder of what we've accomplished together at Pluri including signing a

HAIFA, Israel, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ:PLUR) (TASE: PLUR) ("Pluri" or the "Company"), a biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures, today announced that it is assessing its readiness to initiate mass production of PLX-R18, a novel potential treatment for hematopoietic complications of the acute radiation syndrome (H-ARS) following exposure to nuclear radiation, in response to heightened global tensions and escalating nuclear threats, particularly in Ukraine. PLX-R18 has shown potential promise in significantly improving survival and accelerating recovery from H-ARS in pre

HAIFA, ISRAEL / ACCESSWIRE / November 12, 2024 / Pluri Inc. (NASDAQ:PLUR), a leading biotechnology company that offers cell-based solutions for various industries. The company will be available for 1-on-1 meetings throughout the day in addition to their presentation.Event: Q4 Investor SummitPresentation Time: 9:00am - 9:30am ETLocation: https://www.webcaster4.com/Webcast/Page/3075/51643The theme is 40 micro-cap companies with a catalyst and/or strong performance in the current market.Take a deep dive with the best Investors in MicroCapLive Q & AComplimentary to Qualified Investors. Please REGISTER HERE.About the Investor SummitThe Investor Summit is an exclusive, independent conference dedic

Memorandum of Understanding has been signed NEW YORK, Nov. 11, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that it has entered into a Memorandum of Understanding (MOU) with Pluri Inc. (NASDAQ:PLUR) through its wholly owned subsidiary ("Pluri"), an established global leader in the development and manufacturing of cell-based therapeutics, to manufacture NurOwn® for use in BrainStorm's planned Phase 3b trial in amyotrophic lateral sclerosis (ALS). This MOU enables BrainStorm to begin transfer of its manufacturing technology and start producing NurOwn at Pluri's manufacturing facil

The Israel Innovation Authority will fund Pluri and BIRAD's collaboration to advance MAIT Cell Therapy, led by Professor Cyrille Cohen, Head of the laboratory of tumor immunology and immunotherapy at Bar-Ilan UniversityMAIT cells hold immense potential for immunotherapy and the treatment of solid tumors compared to conventional T-cells, but their expansion has been a challenge until Pluri announced its proprietary MAIT immunotherapy platform in May 2024Global cancer immunotherapy market is expected to reach $312 billion by 2033 HAIFA, Israel, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ:PLUR) (TASE:PLUR) ("Pluri" or the "Company"), a leading biotechnology company that tran

HAIFA, Israel, July 18, 2024 (GLOBE NEWSWIRE) -- Leading biotechnology company Pluri Inc. (NASDAQ:PLUR) (TASE:PLUR) ("Pluri" or the "Company"), which transforms cells into solutions that promote global wellbeing and sustainability, today announced it has signed a tech transfer and manufacturing agreement with Kadimastem Ltd. (TASE: KDST), a clinical stage biotechnology company developing therapeutic cells for ALS and diabetes treatments. PluriCDMO™, launched earlier this year, leverages Pluri's 47,000 square foot good manufacturing practice (GMP) cell production facility to manufacture cell-based products for life science companies. PluriCDMO™ will manufacture two cell therapy product can

HAIFA, Israel, March 06, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ:PLUR) (TASE: PLUR) ("Pluri" or the "Company"), a leading biotech company that transforms cells into solutions that promote global wellbeing and sustainability, today announced the appointment of attorney James Roosevelt, Jr. to the Company's Advisory Board. Having served in public-service positions in Washington, D.C., followed by a successful decade in the private sector as CEO of Tufts Health Plan, Mr. Roosevelt is a trusted and sought-after advisor on business matters, legislative and regulatory issues, governance, and personnel matters. The intersection of public policy and health is a passion for him. As CEO of

HAIFA, Israel, July 13, 2023 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ:PLUR) (TASE: PLUR) ("Pluri" or the "Company"), a leading biotech company that transforms cells into solutions that promote wellbeing and sustainability, today announced the appointment of Lorne Abony to the Company's Board of Directors, effective as of July 11, 2023.  Abony is a successful entrepreneur who has decades of experience building and scaling multi-billion-dollar global businesses – both public and private companies – across multiple industries. He is a globally recognized leader who has invested, directly or indirectly, in more than 20 cellular agriculture and cultivated food companies. Bringing his expertise t

PRE 14A - Pluri Inc. (0001158780) (Filer)

8-K - Pluri Inc. (0001158780) (Filer)

10-Q - Pluri Inc. (0001158780) (Filer)

8-K - Pluri Inc. (0001158780) (Filer)

8-K - Pluri Inc. (0001158780) (Filer)

8-K - Pluri Inc. (0001158780) (Filer)

8-K - Pluri Inc. (0001158780) (Filer)

10-Q - Pluri Inc. (0001158780) (Filer)

8-K - Pluri Inc. (0001158780) (Filer)

10-K - Pluri Inc. (0001158780) (Filer)

4 - Pluri Inc. (0001158780) (Issuer)

4 - Pluri Inc. (0001158780) (Issuer)

4 - Pluri Inc. (0001158780) (Issuer)

4 - Pluri Inc. (0001158780) (Issuer)

4 - Pluri Inc. (0001158780) (Issuer)

4 - Pluri Inc. (0001158780) (Issuer)

4 - Pluri Inc. (0001158780) (Issuer)

3 - Pluri Inc. (0001158780) (Issuer)

3 - Pluri Inc. (0001158780) (Issuer)

4 - Pluri Inc. (0001158780) (Issuer)

Memorandum of Understanding has been signed NEW YORK, Nov. 11, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that it has entered into a Memorandum of Understanding (MOU) with Pluri Inc. (NASDAQ:PLUR) through its wholly owned subsidiary ("Pluri"), an established global leader in the development and manufacturing of cell-based therapeutics, to manufacture NurOwn® for use in BrainStorm's planned Phase 3b trial in amyotrophic lateral sclerosis (ALS). This MOU enables BrainStorm to begin transfer of its manufacturing technology and start producing NurOwn at Pluri's manufacturing facil